SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study
Open accessAbstract
BACKGROUND: SARS-CoV-2 has spread substantially within India over multiple waves of the ongoing COVID-19 pandemic. However, the risk factors and disease burden associated with COVID-19 in India remain poorly understood. We aimed to assess predictors of infection and mortality within an active surveillance study, and to probe the completeness of case and mortality surveillance. METHODS: In this prospective, active surveillance study, we used data collected under expanded programmatic surveillance testing for SARS-CoV-2 in the district of Madurai, Tamil Nadu, India (population of 3 266 000 individuals). Prospective testing via RT-PCR was done in individuals with fever or acute respiratory symptoms as well as returning travellers, frontline workers, contacts of laboratory-confirmed COVID-19 cases, residents of containment zones, patients undergoing medical procedures, and other risk groups. Standardised data collection on symptoms and chronic comorbid conditions was done as part of routine intake. Additionally, seroprevalence of anti-SARS-CoV-2 immunoglobulin G was assessed via a cross-sectional survey recruiting adults across 38 clusters within Madurai District from Oct 19, 2020, to Nov 5, 2020. We estimated adjusted odds ratios (aORs) for positive RT-PCR results comparing individuals by age, sex, comorbid conditions, and aspects of clinical presentation. We estimated case-fatality ratios (CFRs) over the 30-day period following RT-PCR testing stratified by the same variables, and adjusted hazard ratios (aHRs) for death associated with age, sex, and comorbidity. We estimated infection-fatality ratios (IFRs) on the basis of age-specific seroprevalence. RESULTS: Between May 20, 2020, and Oct 31, 2020, 13·5 diagnostic tests were done per 100 inhabitants within Madurai, as compared to 7·9 tests per 100 inhabitants throughout India. From a total of 440 253 RT-PCR tests, 15 781 (3·6%) SARS-CoV-2 infections were identified, with 8720 (5·4%) of 160 273 being positive among individuals with symptoms, and 7061 (2·5%) of 279 980 being positive among individuals without symptoms, at the time of presentation. Estimated aORs for symptomatic RT-PCR-confirmed infection increased continuously by a factor of 4·3 from ages 0-4 years to 80 years or older. By contrast, risk of asymptomatic RT-PCR-confirmed infection did not differ across ages 0-44 years, and thereafter increased by a factor of 1·6 between ages 45-49 years and 80 years or older. Seroprevalence was 40·1% (95% CI 35·8-44·6) at age 15 years or older by the end of the study period, indicating that RT-PCR clinical testing and surveillance testing identified only 1·4% (1·3-1·6%) of all infections in this age group. Among RT-PCR-confirmed cases, older age, male sex, and history of cancer, diabetes, other endocrine disorders, hypertension, other chronic circulatory disorders, respiratory disorders, and chronic kidney disease were each associated with elevated risk of mortality. The CFR among RT-PCR-confirmed cases was 2·4% (2·2-2·6); after age standardisation. At age 15 years or older, the IFR based on reported deaths was 0·043% (0·039-0·049), with reported deaths being only 11·0% (8·2-14·5) of the expected count. INTERPRETATION: In a large-scale SARS-CoV-2 surveillance programme in Madurai, India, we identified equal risk of asymptomatic infection among children, teenagers, and working-age adults, and increasing risk of infection and death associated with older age and comorbidities. Establishing whether surveillance practices or differences in infection severity account for gaps between observed and expected mortality is of crucial importance to establishing the burden of COVID-19 in India. FUNDING: The Bill & Melinda Gates Foundation, the National Science Foundation, and the National Institute of General Medical Sciences. TRANSLATION: For the Hindi translation of the abstract see Supplementary Materials section.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Discrepancies between all-cause and reported COVID-19 mortality in Madurai closely resemble findings in other settings within India, both over time and across demographic strata.
“Discrepancies between all-cause and reported COVID-19 mortality in Madurai closely resemble findings in other settings within India, both over time and across demographic strata3,27,55–58.”
From Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city (2023) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660 · see citing works
Spread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248 · see citing works
A Procedure for Objective Respondent Selection within the Household
Kish, L. (1949) · Journal of the American Statistical Association · doi:10.1080/01621459.1949.10483314 · Cited by 1,218 · see citing works
Age-specific mortality and immunity patterns of SARS-CoV-2
O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021) · Nature · doi:10.1038/s41586-020-2918-0 · Cited by 1,210 · see citing works
Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’
Lavezzo, E., Franchin, E., Ciavarella, C., Cuomo-Dannenburg, G., Barzon, L., Vecchio, C. D., Rossi, L., Manganelli, R., Loregian, A., Navarin, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2488-1 · Cited by 1,050 · see citing works
Karlinsky, A., & Kobak, D. (2021) · eLife · doi:10.7554/elife.69336 · Cited by 772 · see citing works
de Lusignan, S., Dorward, J., Correa, A., Jones, N. R., Akinyemi, O., Amirthalingam, G., Andrews, N., Byford, R. C., Dabrera, G., Elliot, A. J., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30371-6 · Cited by 593 · see citing works
Jing, Q.-L., Liu, M.-J., Zhang, Z.-B., Fang, L.-Q., Yuan, J., Zhang, A.-R., Dean, N. E., Luo, L., Ma, M.-M., Longini, I. M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30471-0 · Cited by 492 · see citing works
Weinberger, D. M., Chen, J., Cohen, T., Crawford, F. W., Mostashari, F., Olson, D., Pitzer, V. E., Reich, N. G., Russi, M., Simonsen, L., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3391 · Cited by 485 · see citing works
Epidemiology and transmission dynamics of COVID-19 in two Indian states
Laxminarayan, R., Wahl, B., Dudala, S. R., Gopal, K., Mohan B, C., Neelima, S., Jawahar Reddy, K. S., Radhakrishnan, J., & Lewnard, J. A. (2020) · Science · doi:10.1126/science.abd7672 · Cited by 485 · see citing works
Self-citationAge and Multimorbidity Predict Death Among COVID-19 Patients
Iaccarino, G., Grassi, G. M., Borghi, C., Ferri, C., Salvetti, M., Volpe, M., Cicero, A. F. G., Minuz, P., Muiesan, M. L., Mulatero, P., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15324 · Cited by 393 · see citing works
Prospective Study of One Million Deaths in India: Rationale, Design, and Validation Results
Jha, P., Gajalakshmi, V., Gupta, P. C., Kumar, R., Mony, P., Dhingra, N., Peto, R., & Collaborators, R.-C. P. S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030018 · Cited by 323 · see citing works
Li, F., Li, Y.-Y., Liu, M.-J., Fang, L.-Q., Dean, N. E., Wong, G., Yang, X.-B., Longini, I. M., Halloran, M. E., Wang, H.-J., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30981-6 · Cited by 242 · see citing works
COVID-19 deaths in Africa: prospective systematic postmortem surveillance study
Mwananyanda, L., Gill, C. J., MacLeod, W., Kwenda, G., Pieciak, R., Mupila, Z., Lapidot, R., Mupeta, F., Forman, L., Ziko, L., et al. (2021) · BMJ · doi:10.1136/bmj.n334 · Cited by 211 · see citing works
The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome
Finlay, B. B., Amato, K. R., Azad, M. B., Blaser, M. J., Bosch, T. C. G., Chu, H., Domínguez-Bello, M. G., Ehrlich, S. D., Elinav, E., Geva‐Zatorsky, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010217118 · Cited by 164 · see citing works
The World Mortality Dataset: Tracking excess mortality across countries during the COVID-19 pandemicPreprint
Karlinsky, A., & Kobak, D. (2021) · medRxiv · doi:10.1101/2021.01.27.21250604 · Cited by 161 · see citing works
Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India
Malani, A., Shah, D., Kang, G., Lobo, G. N., Shastri, J. S., Mohanan, M., Jain, R. K., Agrawal, S. R., Juneja, S., Imad, S., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30467-8 · Cited by 147 · see citing works
Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays?
Plebani, M., Padoan, A., Negrini, D., Carpinteri, B., & Sciacovelli, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.050 · Cited by 102 · see citing works
Fan, V. S., Dominitz, J. A., Eastment, M. C., Locke, E. R., Green, P. K., Berry, K., O’Hare, A. M., Shah, J. A., Crothers, K. A., & Ioannou, G. N. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1624 · Cited by 45 · see citing works
Towards a better health care delivery system: The Tamil Nadu model
Parthasarathi, R., & Sinha, S. (2016) · Indian Journal of Community Medicine · doi:10.4103/0970-0218.193344 · Cited by 41 · see citing works
Low-income countries are more immune to COVID-19: A misconception
Roy, S. D. (2020) · Indian Journal of Medical Sciences · doi:10.25259/ijms_26_2020 · Cited by 37 · see citing works
SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020Preprint
Malani, A., Ramachandran, S., Tandel, V., Parasa, R., Imad, S., Sudharshini, S., Prakash, V., Yogananth, Y., Raju, S., & Selvavinayagam, T. S. (2021) · medRxiv · doi:10.1101/2021.02.03.21250949 · Cited by 20 · see citing works
Reconstructing the COVID-19 epidemic in Delhi, India: infection attack rate and reporting of deathsPreprint
Pons-Salort, M., John, J. K., Watson, O. J., et al. (2021) · medRxiv · doi:10.1101/2021.03.23.21254092 · Cited by 6 · see citing works
Is India's coronavirus death ‘paradox’ vanishing?
Cohen, J. D. (2021) · Science · doi:10.1126/science.372.6542.552 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study
Lewnard, J. A., Mahmud, A., Narayan, T., Wahl, B., Selvavinayagam, T. S., Mohan B, C., & Laxminarayan, R. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00746-5 · Cited by 41 · see citing works
Self-citationAttributed causes of excess mortality during the COVID-19 pandemic in a south Indian city
Lewnard, J. A., B, C. M., Kang, G., & Laxminarayan, R. (2023) · Nature Communications · doi:10.1038/s41467-023-39322-7 · Cited by 23 · see citing works
Self-citation
- Authors
- Laxminarayan, R., B, C. M., G, V. T., Arjun Kumar, K. V., Wahl, B., & Lewnard, J. A.
- Affiliations
- Johns Hopkins University (US)
- Government of Tamil Nadu (IN)
- University of California, Berkeley (US)
- Corresponding author
- Lewnard, Joseph A
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 21
- Issue
- 12
- Pages
- 1665-1676
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC8363227
- OpenAlex
- W3195977920
- Cited by
- 43
- References
- 24
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 12 · 2022: 19 · 2021: 4
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Bill and Melinda Gates Foundation (INV029062)
- National Science Foundation (CCF1918628)
- National Institutes of Health
- National Institute of General Medical Sciences (MIDASNI2020-3)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- SARS-CoV-2, COVID-19 pandemic, Madurai, infection fatality rate, case fatality rate, seroprevalence, asymptomatic infection, risk factors, comorbidities, mortality surveillance, RT-PCR testing, contact tracing, Tamil Nadu, active surveillance, containment zones, frontline workers
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, India, Infant, Infant, Newborn, Male, Middle Aged, Population Surveillance, Prospective Studies, Risk Factors, Seroepidemiologic Studies, Young Adult, Asymptomatic Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
